"The state has an obligation to protect all girls," Rousseff said yesterday as she inaugurated the program in Sao Paulo.
Brazil intends over five years to produce a vaccine in conjunction with biomedical research center Butantan Institute and US pharmaceutical company Merck Sharp & Dohme (MSD) via a USD 480 million investment, making available 41 million doses over that time frame until Brazil's labs can produce their own.
The World Health Organisation says cervical cancer is the second most common form of the disease in women worldwide, each year bringing 250,000 deaths and 500,000 new cases.